Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 335

1.

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.

Ocaña A, Amir E, Pandiella A.

Breast Cancer Res. 2020 Jan 31;22(1):15. doi: 10.1186/s13058-020-1252-7. Review.

2.

Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability.

Altaha MA, Nolan M, Marwick TH, Somerset E, Houbois C, Amir E, Yip P, Connelly KA, Michalowska M, Sussman MS, Wintersperger BJ, Thavendiranathan P.

JACC Cardiovasc Imaging. 2019 Dec 18. pii: S1936-878X(19)31013-7. doi: 10.1016/j.jcmg.2019.10.016. [Epub ahead of print]

PMID:
31864977
3.

Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3).

Tran B, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Fankhauser C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Garcia Del Muro X, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DYC, Bedard PL.

Cancer Med. 2020 Jan;9(1):116-124. doi: 10.1002/cam4.2674. Epub 2019 Nov 12.

4.

Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV: A Systematic Review and Meta-analysis.

Sorotsky H, Hogg D, Amir E, Araujo DV.

JAMA Netw Open. 2019 Nov 1;2(11):e1914816. doi: 10.1001/jamanetworkopen.2019.14816. No abstract available.

5.

Undisclosed Financial Conflicts of Interest of Authors of Clinical Drug Trials Published in Influential Medical Journals: A Cohort Study.

Tau N, Shochat T, Gafter-Gvili A, Amir E, Shepshelovich D.

Mayo Clin Proc. 2019 Nov;94(11):2272-2276. doi: 10.1016/j.mayocp.2019.08.025.

PMID:
31685153
6.

The evaluation of ocular refractive error and axial length changes after scleral buckle removal.

Hosein AM, Rana S, Amir EM, Habib O, Amin N.

J Family Med Prim Care. 2019 Sep 30;8(9):2950-2952. doi: 10.4103/jfmpc.jfmpc_557_19. eCollection 2019 Sep.

7.

Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis.

Saleh RR, Peinado P, Fuentes-Antrás J, Pérez-Segura P, Pandiella A, Amir E, Ocaña A.

Front Oncol. 2019 Oct 15;9:1040. doi: 10.3389/fonc.2019.01040. eCollection 2019.

8.

Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome.

Noblejas-López MDM, Nieto-Jiménez C, Morcillo García S, Pérez-Peña J, Nuncia-Cantarero M, Andrés-Pretel F, Galán-Moya EM, Amir E, Pandiella A, Győrffy B, Ocana A.

Oncoimmunology. 2019 Jul 3;8(10):e1629780. doi: 10.1080/2162402X.2019.1629780. eCollection 2019.

PMID:
31646075
9.

Single-cell immune landscape of human atherosclerotic plaques.

Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir ED, Amadori L, Khan NS, Wong CK, Shamailova R, Hill CA, Wang Z, Remark R, Li JR, Pina C, Faries C, Awad AJ, Moss N, Bjorkegren JLM, Kim-Schulze S, Gnjatic S, Ma'ayan A, Mocco J, Faries P, Merad M, Giannarelli C.

Nat Med. 2019 Oct;25(10):1576-1588. doi: 10.1038/s41591-019-0590-4. Epub 2019 Oct 7.

PMID:
31591603
10.

A critique of the fragility index.

Desnoyers A, Nadler MB, Wilson BE, Amir E.

Lancet Oncol. 2019 Oct;20(10):e552. doi: 10.1016/S1470-2045(19)30583-2. Epub 2019 Sep 30. No abstract available.

PMID:
31578994
11.

Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation.

Abdel-Qadir H, Thavendiranathan P, Fung K, Amir E, Austin PC, Anderson GS, Lee DS.

JAMA Netw Open. 2019 Sep 4;2(9):e1911838. doi: 10.1001/jamanetworkopen.2019.11838.

12.

Association Between Data Sources and US Food and Drug Administration Drug Safety Communications.

Tau N, Shochat T, Gafter-Gvili A, Tibau A, Amir E, Shepshelovich D.

JAMA Intern Med. 2019 Sep 3. doi: 10.1001/jamainternmed.2019.3066. [Epub ahead of print] No abstract available.

PMID:
31479104
13.
14.

Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals.

Shepshelovich D, Yahav D, Tibau A, Amir E.

Eur J Intern Med. 2020 Jan;71:45-49. doi: 10.1016/j.ejim.2019.08.009. Epub 2019 Aug 19.

PMID:
31439377
15.

Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.

Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, Thavendiranathan P.

JAMA Cardiol. 2019 Aug 21. doi: 10.1001/jamacardio.2019.2952. [Epub ahead of print]

PMID:
31433450
16.

A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).

Chia S, Bedard PL, Hilton J, Amir E, Gelmon K, Goodwin R, Villa D, Cabanero M, Tu D, Tsao M, Seymour L.

Oncologist. 2019 Nov;24(11):1439-1445. doi: 10.1634/theoncologist.2019-0321. Epub 2019 Aug 16.

17.

A Modified Injector and Sample Acquisition Protocol Can Improve Data Quality and Reduce Inter-Instrument Variability of the Helios Mass Cytometer.

Lee BH, Kelly G, Bradford S, Davila M, Guo XV, Amir ED, Thrash EM, Solga MD, Lannigan J, Sellers B, Candia J, Tsang J, Montgomery RR, Tamaki SJ, Sigdel TK, Sarwal MM, Lanier LL, Tian Y, Kim C, Hinz D, Peters B, Sette A, Rahman AH.

Cytometry A. 2019 Sep;95(9):1019-1030. doi: 10.1002/cyto.a.23866. Epub 2019 Jul 30.

PMID:
31364278
18.

Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis.

Goldvaser H, Korzets Y, Shepshelovich D, Yerushalmi R, Sarfaty M, Ribnikar D, Thavendiranathan P, Amir E.

JNCI Cancer Spectr. 2019 May 11;3(2):pkz033. doi: 10.1093/jncics/pkz033. eCollection 2019 Jun.

19.

Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines.

Saleh RR, Majeed H, Tibau A, Booth CM, Amir E.

Cancer. 2019 Nov 15;125(22):4069-4075. doi: 10.1002/cncr.32408. Epub 2019 Jul 29.

PMID:
31355923
20.

The Effect of Exercise on Quality of Life, Fatigue, Physical Function, and Safety in Advanced Solid Tumor Cancers: A Meta-analysis of Randomized Control Trials.

Nadler MB, Desnoyers A, Langelier DM, Amir E.

J Pain Symptom Manage. 2019 Nov;58(5):899-908.e7. doi: 10.1016/j.jpainsymman.2019.07.005. Epub 2019 Jul 15. Review.

PMID:
31319105
21.

Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study.

Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu JV, Fung K, Anderson GM.

Eur Heart J. 2019 Dec 21;40(48):3913-3920. doi: 10.1093/eurheartj/ehz460.

PMID:
31318428
22.

Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy.

Hartmann FJ, Babdor J, Gherardini PF, Amir ED, Jones K, Sahaf B, Marquez DM, Krutzik P, O'Donnell E, Sigal N, Maecker HT, Meyer E, Spitzer MH, Bendall SC.

Cell Rep. 2019 Jul 16;28(3):819-831.e4. doi: 10.1016/j.celrep.2019.06.049.

23.

Response to: Assessing the risk of bias and publication bias should be integral parts of the systematic review.

McNamara MG, Amir E.

Eur J Cancer. 2019 Sep;118:189. doi: 10.1016/j.ejca.2019.05.026. Epub 2019 Jul 2. No abstract available.

PMID:
31277809
24.

Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis.

Rodríguez-Fernández IA, Rodríguez-Romo L, Hernandez-Barajas D, Gonzalez-Conchas GA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE.

Eur Urol Oncol. 2019 Jul;2(4):448-455. doi: 10.1016/j.euo.2018.10.003. Epub 2018 Nov 5. Review.

PMID:
31277782
25.

CMR and Tissue Characterization: Don't Forget the Strain!

Connelly KA, Yan AT, Amir E, Thavendiranathan P.

J Am Coll Cardiol. 2019 Jul 2;73(25):3359. doi: 10.1016/j.jacc.2019.03.521. No abstract available.

PMID:
31248561
26.

Development of a Comprehensive Antibody Staining Database Using a Standardized Analytics Pipeline.

Amir ED, Lee B, Badoual P, Gordon M, Guo XV, Merad M, Rahman AH.

Front Immunol. 2019 Jun 11;10:1315. doi: 10.3389/fimmu.2019.01315. eCollection 2019.

27.

Assisting with Decision-Making: How Standardized Information Impacts Breast Cancer Patient Decisions Regarding Fertility Trade-Offs and Chemotherapy.

Srikanthan A, Amir E, Gupta A, Baxter N, Kennedy ED.

J Adolesc Young Adult Oncol. 2019 Dec;8(6):660-667. doi: 10.1089/jayao.2019.0027. Epub 2019 Jun 26.

PMID:
31241397
28.

Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis.

Saleh RR, Antrás JF, Peinado P, Pérez-Segura P, Pandiella A, Amir E, Ocaña A.

Cancer Treat Rev. 2019 Jul;77:11-19. doi: 10.1016/j.ctrv.2019.05.006. Epub 2019 May 29.

PMID:
31174180
29.

The Voices of Young Women with Breast Cancer: Providing Support and Information for Improved Fertility Preservation Discussions.

Srikanthan A, Ethier JL, Amir E.

J Adolesc Young Adult Oncol. 2019 Oct;8(5):547-553. doi: 10.1089/jayao.2019.0030. Epub 2019 Jun 3.

PMID:
31158039
30.

PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis.

Ghate K, Amir E, Kuksis M, Hernandez-Barajas D, Rodriguez-Romo L, Booth CM, Vera-Badillo FE.

Cancer Treat Rev. 2019 Jun;76:51-56. doi: 10.1016/j.ctrv.2019.05.002. Epub 2019 May 16.

PMID:
31125908
31.

The Impact of Big Data Research on Practice, Policy, and Cancer Care.

Chambers DA, Amir E, Saleh RR, Rodin D, Keating NL, Osterman TJ, Chen JL.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e167-e175. doi: 10.1200/EDBK_238057. Epub 2019 May 17. Review.

32.

Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment.

Gyawali B, Hwang TJ, Vokinger KN, Booth CM, Amir E, Tibau A.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:374-387. doi: 10.1200/EDBK_242229. Epub 2019 May 17.

33.

Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer-the 5C study: a study protocol for a randomised controlled phase III trial.

Puts MTE, Hsu T, Mariano C, Monette J, Brennenstuhl S, Pitters E, Ray J, Wan-Chow-Wah D, Kozlowski N, Krzyzanowska M, Amir E, Elser C, Jang R, Prica A, Krahn M, Beland F, Bergman S, Koneru R, Lemonde M, Szumacher E, Zidulka J, Fung S, Li A, Emmenegger U, Mehta R, Flemming K, Breunis H, Alibhai SMH.

BMJ Open. 2019 May 10;9(5):e024485. doi: 10.1136/bmjopen-2018-024485.

34.

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.

Morcillo-Garcia S, Noblejas-Lopez MDM, Nieto-Jimenez C, Perez-Peña J, Nuncia-Cantarero M, Győrffy B, Amir E, Pandiella A, Galan-Moya EM, Ocana A.

PLoS One. 2019 Apr 16;14(4):e0209134. doi: 10.1371/journal.pone.0209134. eCollection 2019.

35.

Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis.

Korzets Y, Fyles A, Shepshelovich D, Amir E, Goldvaser H.

Breast Cancer Res Treat. 2019 Jun;175(3):531-545. doi: 10.1007/s10549-019-05209-9. Epub 2019 Mar 30. Review.

PMID:
30929116
36.

Role of Bisphosphonates in Breast Cancer Therapy.

Goldvaser H, Amir E.

Curr Treat Options Oncol. 2019 Mar 14;20(4):26. doi: 10.1007/s11864-019-0623-8. Review.

PMID:
30874905
37.

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations.

Jiang DM, Chan KKW, Jang RW, Booth C, Liu G, Amir E, Mason R, Everest L, Elimova E.

Cancer Med. 2019 Apr;8(4):1584-1593. doi: 10.1002/cam4.2058. Epub 2019 Mar 7.

38.

Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.

Flaum N, Hubner RA, Valle JW, Amir E, McNamara MG.

J Surg Oncol. 2019 Jun;119(7):932-940. doi: 10.1002/jso.25440. Epub 2019 Mar 5.

PMID:
30838647
39.

Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.

Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S, Amir E, Thavendiranathan P.

Can J Cardiol. 2019 Feb;35(2):153-159. doi: 10.1016/j.cjca.2018.11.028. Epub 2018 Dec 4.

PMID:
30760421
40.

The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.

Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu JV, Fung K, Anderson GM.

J Natl Cancer Inst. 2019 Aug 1;111(8):854-862. doi: 10.1093/jnci/djy218.

41.

Endpoint selection in HER2-positive early breast cancer.

Amir E.

Lancet Oncol. 2019 Mar;20(3):315-316. doi: 10.1016/S1470-2045(18)30779-4. Epub 2019 Jan 29. No abstract available.

PMID:
30709632
42.

Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.

Shepshelovich D, Tibau A, Goldvaser H, Ocana A, Seruga B, Amir E.

Mayo Clin Proc. 2019 Jan;94(1):74-83. doi: 10.1016/j.mayocp.2018.07.027.

PMID:
30611457
43.

Pilot Study of a Transitional Intervention for Family Caregivers of Older Adults.

McCusker J, Lambert SD, Yaffe MJ, Cole MG, Hidalgo M, Amir E, de Raad M, Belzile E.

Can J Aging. 2018 Dec 27:1-12. doi: 10.1017/S071498081800051X. [Epub ahead of print]

PMID:
30587251
44.

Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual.

Shepshelovich D, Tibau A, Molto C, Goldvaser H, Ocana A, Šeruga B, Amir E.

JAMA Oncol. 2019 Jan 1;5(1):107-109. doi: 10.1001/jamaoncol.2018.5877. No abstract available.

45.

An integrated framework using high-dimensional mass cytometry and fluorescent flow cytometry identifies discrete B cell subsets in patients with red meat allergy.

Cox KM, Commins SP, Capaldo BJ, Workman LJ, Platts-Mills TAE, Amir ED, Lannigan JA, Schuyler AJ, Erickson LD.

Clin Exp Allergy. 2019 May;49(5):615-625. doi: 10.1111/cea.13322. Epub 2019 Jan 8.

PMID:
30506749
46.

A prospective intervention to improve happiness and reduce burnout in oncologists.

Clemons M, Mazzarello S, Pond G, Amir E, Asmis T, Berry S, Brackstone M, Brule S, Goodwin R, Hilton JF, Julião M, Nicholas G, Stewart DJ, Wheatley-Price P, Cholmsky L, Krentel A, Hutton B, Joy AA.

Support Care Cancer. 2019 Apr;27(4):1563-1572. doi: 10.1007/s00520-018-4567-5. Epub 2018 Nov 30.

PMID:
30506102
47.

Competing risks of extended adjuvant aromatase inhibitors.

Amir E.

Lancet Oncol. 2019 Jan;20(1):8-9. doi: 10.1016/S1470-2045(18)30663-6. Epub 2018 Nov 30. No abstract available.

PMID:
30509770
48.

Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study.

Kitchlu A, McArthur E, Amir E, Booth CM, Sutradhar R, Majeed H, Nash DM, Silver SA, Garg AX, Chan CT, Kim SJ, Wald R.

J Natl Cancer Inst. 2018 Nov 13. doi: 10.1093/jnci/djy167. [Epub ahead of print]

49.

Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.

McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E.

Eur J Cancer. 2018 Dec;105:1-9. doi: 10.1016/j.ejca.2018.09.031. Epub 2018 Oct 29.

PMID:
30384012
50.

Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis.

Goldvaser H, Ribnikar D, Majeed H, Ocaña A, Amir E.

Cancer Treat Rev. 2018 Dec;71:68-75. doi: 10.1016/j.ctrv.2018.10.010. Epub 2018 Oct 17. Review.

PMID:
30366201

Supplemental Content

Support Center